Morningstar

Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty

Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing ...
Morningstar

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for ...
Times Argus

Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of ...

Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA ® lidocaine range of Restylane ...
Times Argus

Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty

Ongoing clinical evidence continues to reinforce Restylane’s ability to deliver natural-looking, long-lasting results across multiple indications. 8-11 New clinical data presented at IMCAS ...

Galderma Announces Triple Approval of New State-of-the-Art Restylane Syringe in the EU, the U.S., and Canada, Reaffirming the Company's Position at the Forefront of Injectable ...

Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylanesyringe for use with a range of Restylane NASHA lidocaine products ...